# Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia

> **NCT05613322** · — · TERMINATED · sponsor: **Resistell AG** · enrollment: 246 (actual)

## Conditions studied

- Bacteremia Sepsis

## Interventions

- **DIAGNOSTIC_TEST:** Resistell Phenotech

## Key facts

- **NCT ID:** NCT05613322
- **Lead sponsor:** Resistell AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-18
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-09-05
- **Target enrollment:** 246 (ACTUAL)
- **Why stopped:** Statistical power for primary endpoint (sensitivity) for E. coli and K. pneumoniae and ceftriaxone was achieved
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05613322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05613322, "Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05613322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*